Annexon, Inc. (ANNX) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Annexon, Inc.
Reporting Period: Fiscal year ended December 31, 2025.
Business Overview: Annexon is a clinical-stage biopharmaceutical company developing targeted immunotherapies for complement-mediated neuroinflammatory diseases. The company focuses on inhibiting the classical complement pathway at the C1q level. It has no products approved for commercial sale and has incurred significant losses since inception.
Key Pipeline Assets:
- Tanruprubart: Investigational therapy for Guillain-Barré Syndrome (GBS). Filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in January 2026. Plans to submit a Biologics License Application (BLA) to the FDA in 2026 following data from the FORWARD study.
- Vonaprument: Investigational therapy for Geographic Atrophy (GA). Completed enrollment of 659 patients in the Phase 3 ARCHER II trial in July 2025. Topline data expected in Q4 2026.
- ANX1502: Novel oral small molecule for autoimmune conditions. Ongoing proof-of-concept study in Cold Agglutinin Disease (CAD).
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(206,690) | $(138,200) |
| Research & Development Expenses | $184,698 | $119,448 |
| General & Administrative Expenses | $31,709 | $34,625 |
| Cash, Cash Equivalents & Short-Term Investments | $238,345 | $312,017 |
| Accumulated Deficit | $(917,389) | $(710,699) |
| Net Cash Used in Operating Activities | $(186,356) | $(118,006) |
Note: The filing text does not provide specific margin or debt figures as the company has no revenue and no long-term debt reported in the balance sheet summary.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately 50% to $206.7 million in 2025 from $138.2 million in 2024.
- R&D Expense Surge: R&D expenses increased by 55% ($65.3 million). This was driven by a 133% increase in contract manufacturing costs (supporting tanruprubart regulatory submissions and vonaprument technology transfer) and a 58% increase in clinical/nonclinical outside services (ARCHER II trial and FORWARD study).
- G&A Expense Decrease: G&A expenses decreased by 8% ($2.9 million) due to corporate efficiencies and reduced consulting fees, partially offset by higher headcount.
- Financing Activity: The company raised approximately $80.5 million in net proceeds in November 2025 through the sale of common stock and pre-funded warrants. It also utilized its At-The-Market (ATM) program, raising $27.4 million in 2025.
- Cash Position: Despite operating losses, cash and short-term investments increased from $312.0 million in 2024 to $238.3 million in 2025 (Note: The text states $238.3 million as of Dec 31, 2025, but the balance sheet shows $162M cash + $76M short-term investments = $238M. The 2024 balance sheet shows $49M cash + $262M short-term investments = $311M. The decrease in total liquidity is attributed to operating burn and investment activity).
Guidance, Outlook, and Risks
Outlook and Guidance:
- Liquidity: Management believes existing cash resources ($238.3 million) will fund operating expenses into the second half of 2027.
- Regulatory Milestones:
- Tanruprubart: Awaiting EMA review of MAA filed Jan 2026. Plans to submit FDA BLA in 2026 pending FORWARD study data.
- Vonaprument: Topline data from Phase 3 ARCHER II trial expected in Q4 2026.
- ANX1502: Update on CAD proof-of-concept study expected in 2026.
Key Risks and Contingencies:
- Capital Requirements: The company requires substantial additional financing to achieve its goals. Failure to obtain capital could force delays or termination of programs.
- Regulatory Uncertainty: FDA has indicated that the current data package for tanruprubart (based on non-U.S. trials) may not be sufficient for BLA approval without additional Western patient data from the FORWARD study.
- Development Risk: No products are approved. Clinical trials are inherently risky, and failure to meet endpoints or safety issues could halt development.
- Manufacturing: Reliance on third-party suppliers for all manufacturing; supply chain disruptions could impact trials and commercialization.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "second half of 2027" funding estimate given the 50% increase in net loss and high burn rate.
- Regulatory Alignment: Monitor FDA feedback on the tanruprubart data package and the sufficiency of the FORWARD study to support a U.S. BLA.
- Phase 3 Data: Await Q4 2026 topline data for vonaprument in the ARCHER II trial, which is critical for the company's ophthalmology strategy.
- Dilution Risk: Review the terms of the new $150 million ATM program and outstanding pre-funded warrants (42.3 million shares) for potential dilution impact.
- Manufacturing Scale-up: Confirm progress on technology transfers and commercial manufacturing capacity for tanruprubart and vonaprument.